Thermo Fisher Scientific HMHA1/HA-1 Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

1:2,000-1:10,000

-

Immunoprecipitation (IP)

2-10 µg/mg lysate

-

Product Specifications

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Region between residue 100 to 150 of human Minor histocompatibility protein HA-1 [Cleaved into: Minor histocompatibility antigen HA-1. if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:HMHA1,uniProtId:Q92619-1,ncbiNodeId:9606,antigenRange:100-150,antigenLength:1136,antigenImageFileName:A304-862A-M_HMHA1_Q92619-1_Rabbit.svg,antigenImageFileNamePDP:A304-862A-M_HMHA1_Q92619-1_Rabbit_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Storage conditions

4° C

Shipping conditions

Wet ice

Product Specific Information

The recommended shelf life for this product is 1 year from date of receipt.

Target Information

Contains a GTPase activator for the Rho-type GTPases (RhoGAP) domain that would be able to negatively regulate the actin cytoskeleton as well as cell spreading. However, also contains N-terminally a BAR-domain which is able to play an autoinhibitory effect on this RhoGAP activity. Precursor of the histocompatibility antigen HA-1. More generally, minor histocompatibility antigens (mHags) refer to immunogenic peptide which, when complexed with MHC, can generate an immune response after recognition by specific T-cells. The peptides are derived from polymorphic intracellular proteins, which are cleaved by normal pathways of antigen processing. The binding of these peptides to MHC class I or class II molecules and its expression on the cell surface can stimulate T-cell responses and thereby trigger graft rejection or graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation from HLA-identical sibling donor. GVHD is a frequent complication after bone marrow transplantation (BMT), due to mismatch of minor histocompatibility antigen in HLA-matched sibling marrow transplants. Specifically, mismatching for mHag HA-1 which is recognized as immunodominant, is shown to be associated with the development of severe GVHD after HLA-identical BMT. HA-1 is presented to the cell surface by MHC class I HLA-A*0201, but also by other HLA-A alleles. This complex specifically elicits donor-cytotoxic T-lymphocyte (CTL) reactivity against hematologic malignancies after treatment by HLA-identical allogenic BMT. It induces cell recognition and lysis by CTL.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.